Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation

AAPS PharmSciTech

Volumn 16, Issue 6, 2015, Pages 1299-1306

  Fabio, Karine ^a   Curley, Kieran ^a   Guarneri, Joseph ^a   Adamo, Benoit ^a   Laurenzi, Brendan ^a   Grant, Marshall ^a   Offord, Robin ^b   Kraft, Kelly ^a   Leone Bay, Andrea ^a  

^a MannKind Corporation   (United States)

^b Mintaka Foundation   (Switzerland)

Author keywords

dry powder; oral inhalation; oxytocin; peptide delivery; postpartum hemorrhage

Indexed keywords

CITRATE SODIUM; CITRIC ACID; ISOLEUCINE; OXYTOCIN; POVIDONE; TREHALOSE; ZINC DERIVATIVE; AEROSOL; EXCIPIENT; NANOPARTICLE; POWDER;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRY POWDER INHALER; GLASS TRANSITION TEMPERATURE; HUMAN; LASER DIFFRACTION; LIQUID CHROMATOGRAPHY; PARTICLE SIZE; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPRAY DRYING; AEROSOL; CHEMISTRY; DESICCATION; HEAT; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; POWDER; PROCEDURES; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DESICCATION; DRUG COMPOUNDING; DRUG STABILITY; DRY POWDER INHALERS; EXCIPIENTS; HOT TEMPERATURE; NANOPARTICLES; OXYTOCIN; PARTICLE SIZE; POWDERS; TREHALOSE; X-RAY DIFFRACTION;

EID: 84949094970     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0314-0     Document Type: Article

References (29)

1. Dept. of Reproductive Health and Research, WHO WHO recommendations for the prevention and treatment of postpartum hemorrhage; 2012.
2. Guastella AJ, Hickie IB, McGuinness MM, et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology. 2013;38(5):612–25.
3. Hogerzeil HV, Walker GJA, de Goeje MJ. Stability of injectable oxytocics in tropical climates. WHOreportWHO/DAP/93.6;1993.
4. Groot ANJA, Vree TB, Hogerzeil HV, Walker GJA. Stability of oral oxytocics in tropical climates: Results of simulation studies on oral ergometrine, oral ethylergometrine, buccal oxytocin and buccal desamino-oxytocin. Geneva: World Health Organization; 1997.
5. Prankerd RJ, Nguyen T-H, Ibrahim JP, et al. Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum hemorrhage in developing countries. PLoS ONE. 2013;8(12):e82965.
6. Hawe A, Poole R, Romeijn S, Kasper P, Jiskoot W. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res. 2009;26(7):1679–88.
7. Avanti C, Amorij JP, Setyaningsih D, Hawe A. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. The AAPS Journal. 2011;13(2):284–90.
8. Patton J, Byron P. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.
9. Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int J Pharm. 2013;447(1–2):251–80.
10. Manning MC, Chou D, Murphy B, Payne R, Katayama D. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75.
11. Chang L, Pikal M. Mechanisms of protein stabilization in the solid state. J Pharm Sci. 2009;98:2886–908.
12. Carvalho T, Peters J, Williams R. Influence of particle size on regional lung deposition–what evidence is there? Int J Pharm. 2011;406(1–2):1–10.
13. Reinhard V. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022.
14. Elversson J, Millqvist-Fureby A, Alderborn G, Elofsson U. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci. 2003;92:900–10.
15. Liao YH, Brown M, Nazir T, Quader A, Martin G. Effects of sucrose and trehalose on the preservation of the native structure of spray-dried lysozyme. Pharm Res. 2002;19(12):1847–53.
16. Mozziconacci O, Schöneich C. Photodegradation of oxytocin and thermal stability of photoproducts. J Pharm Sci. 2012;101(9):3331–46.
17. Avanti C, Permentier HP, van Dam A, et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm. 2012;9(3):554–62.
18. Christina Avanti C, Hinrichs W, Casini A, et al. The formation of oxytocin dimers is suppressed by the zinc–aspartate–oxytocin complex. J Pharm Sci. 2013;102(6):1734–41.
19. Liu D, Seuthe AB, Ehrler OT, et al. Oxytocin-receptor binding: why divalent metals are essential. J Am Chem Soc. 2005;127(7):2024–5.
20. Wyttenbach T, Liu D, Bowers MT. Interactions of the hormone oxytocin with divalent metal ions. J Am Chem Soc. 2008;130(18):5993–6000.
21. Smutney C, Kinsey PS, Sahi C, Adamo B, Polidoro J, McLean S, et al. Dry powder inhaler and system for drug delivery, MannKind Corporation. USA Patent 8,636,001 B2.
22. Adamo B, Shah S, Smutney C. Inhaler adaptor for a laser diffraction apparatus and method for measuring particle size distribution, MannKind Corporation. USA Patent 8,508,732 B2.
23. Smutney C, Adamo B, Laurenzi B, Kinsey PS. Dry powder drug delivery system and methods, MannKind Corporation. USA Patent Appln. US2014/001106 A1.
24. Adamo B, Polidoro J, Overfield D, Sahi C, Laurenzi B, Smutney C, Kinsey PS. Apparatus and method for simulating inhalation efforts, MannKind Corporation. USA Patent Appln. US 2012/0247235 A1.
25. Lechuga-Ballesteros D, Charan C, Stults C, Stevenson C, Miller D, Vehring R, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97(1):287–302.
26. Tarelli E, Corran PH, Bingham BR, Mollison H, Wait R. Lysine vasopressin undergoes rapid glycation in the presence of reducing sugars. J Pharm Biomed Anal. 1994;12(11):1355–61.
27. Wolfenden R, Yuan Y. Rates of spontaneous cleavage of glucose, fructose, sucrose, and trehalose in water, and the catalytic proficiencies of invertase and trehalas. J Am Chem Soc. 2008;130(24):7548–9.
28. Poole R, Kasper P, Jiskoot W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations. J Pharm Sci. 2011;100:3018–22.
29. Yamashiro D, Hope D, du Vigneaud V. Isomeric dimers of oxytocin. J Am Chem Soc. 1968;90(14):3857–60.